Wolverine Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wolverine Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,400	Closed	-$742K	–	2170
2021 Q4	$742K	Hold	8,400	–	–	0.01%	905
2021 Q3	$649K	Hold	8,400	–	–	0.01%	893
2021 Q2	$700K	Hold	8,400	–	–	0.01%	778
2021 Q1	$634K	Buy	8,400 +8,000	+2,000%	+$654K	0.01%	820
2020 Q4	$35K	Buy	+400	New	+$31.7K	﹤0.01%	1382
2019 Q3	–	Sell	-6,700	Closed	-$573K	–	1396
2019 Q2	$573K	Hold	6,700	–	–	0.01%	805
2019 Q1	$595K	Buy	+6,700	New	+$621K	0.01%	806
2014 Q3	–	Sell	-8	Closed	-$3K	–	2455
2014 Q2	$3K	Buy	+8	New	+$483	﹤0.01%	2091

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management's BMRN Position: Q1 2023 in Review

Wolverine Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 61 shares — an estimated $6.31K sold.

Wolverine Asset Management first reported a position in BMRN in Q2 2014 and held it in 17 quarters. The position peaked at $1.49M in Q1 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Wolverine Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 61 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $6.31K.
Wolverine Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 17 quarters.
Wolverine Asset Management's BioMarin Pharmaceuticals position peaked at $1.49M in Q1 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.